Morgan Stanley downgraded Novo Nordisk to underweight from equal-weight saying it sees slowing growth of its lucrative GLP-1 ...

Parker Waichman, a national law firm, has now filed multiple lawsuits where each Plaintiff alleged that he or she developed NAION after taking Novo ...

Novo Nordisk, the Danish maker of blockbuster drugs Ozempic and Wegovy, caught another downgrade Monday as analysts foresee ...

Federal health officials are cracking down on telehealth companies’ promotion of unapproved versions of prescription drugs.

As India grapples with a surge in lifestyle-related illnesses, the approval of Ozempic marks more than just a new diabetes ...

Novo Nordisk is looking into whether the active ingredient in Ozempic and Wegovy can help Alzheimer’s patients. It could have ...

Novo Nordisk was downgraded to underweight by Morgan Stanley. Morgan Stanley analysts say a trial to test whether Novo Nordisk's blockbuster weight-loss drug also will work against Alzheimer's is ...

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target ...

Thousands of NHS patients are believed to be missing out. And with the NHS tightly restricting access, some working in the ...

Danish pharmaceutical company Novo Nordisk is preparing to introduce its innovative weight management drug, Ozempic ...

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's ...

Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 (the “Class Period”), may, no later than September 30, 2025, seek to be appointed as a ...